Ophthalmology Times

Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases

Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden ...
Ophthalmology Times

Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more ...
Ophthalmology Times

Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy

Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...
Ophthalmology Times

Study update: Cenegermin for moderate or severe neurotrophic keratopathy

Recently reported findings indicate that cenegermin-bkbj ophthalmic solution (Oxervate; Dompé) may perform as an effective ...
Ophthalmology Times

Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease

Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...